HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain.” Artificial ...

Later, Gerhard Lang commercialised the idea by making it more Christmassy. Adding chocolates to the advent calendars, hanging giant advent calendars from buildings in Germany are popular in the ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Two types of calendars for next year given to Pasigueños sparked comparisons on social media. On Sunday, December 22, a Pasig City resident uploaded a photo featuring two different calendars for ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...